New combo aims to outsmart recurrent breast cancer in phase 2 trial
NCT ID NCT06849947
First seen Jan 09, 2026 · Last updated May 11, 2026 · Updated 20 times
Summary
This study tests whether a combination of fulvestrant and ribociclib works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-) that came back after they finished a previous targeted therapy. About 272 adults will be randomly assigned to receive either the two-drug combo or their doctor's choice of treatment. The main goal is to see how long the cancer stays under control, while also tracking side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.